Benefit-risk assessment of infliximab in the treatment of rheumatoid arthritis (Q35031727)

5 August 2017

1 reference

title

Benefit-risk assessment of infliximab in the treatment of rheumatoid arthritis (English)

1 reference

5 August 2017

1 reference

1

Ted R Mikuls

1 reference

5 August 2017

Larry W Moreland

2

1 reference

5 August 2017

publication date

1 January 2003

1 reference

5 August 2017

1 reference

5 August 2017

volume

26

1 reference

5 August 2017

issue

1

1 reference

5 August 2017

page(s)

23-32

1 reference

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides

5 August 2017

cites work

1 reference

12 December 2020

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

1 reference

12 December 2020

Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?

1 reference

12 December 2020

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

1 reference

12 December 2020

Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials

1 reference

12 December 2020

Elevated circulating levels of tumor necrosis factor in severe chronic heart failure

1 reference

12 December 2020

Successful desensitization and therapeutic use of infliximab in adult and pediatric Crohn's disease patients with prior anaphylactic reaction

1 reference

12 December 2020

Corynebacterium parvum- and Mycobacterium bovis bacillus Calmette-Guerin-induced granuloma formation is inhibited in TNF receptor I (TNF-RI) knockout mice and by treatment with soluble TNF-RI

1 reference

12 December 2020

Guidelines for monitoring drug therapy in rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines

1 reference

12 December 2020

Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology

1 reference

12 December 2020

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

1 reference

12 December 2020

1 reference

12 December 2020

Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy.

1 reference

12 December 2020

Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. The Cooperative Systematic Studies of Rheumatic Diseases Group

1 reference

12 December 2020

Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis

1 reference

12 December 2020

Treatment of inflammatory diseases: safety of long-term use of infliximab

1 reference

12 December 2020

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

1 reference

12 December 2020

Measurement of patient outcome in arthritis

1 reference

12 December 2020

TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group

1 reference

12 December 2020

TNF-alpha inhibition: the need for a tumor necrosis factor thermostat

1 reference

12 December 2020

Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α

1 reference

12 December 2020

Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure.

1 reference

12 December 2020

Dilated Cardiomyopathy in Transgenic Mice With Cardiac-Specific Overexpression of Tumor Necrosis Factor-α

1 reference

12 December 2020

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

1 reference

12 December 2020

Comorbidity in rheumatoid arthritis.

1 reference

12 December 2020

Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept

1 reference

12 December 2020

Pharmacokinetic considerations in the treatment of inflammatory bowel disease

1 reference

12 December 2020

The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials

1 reference

12 December 2020

Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2.

1 reference

12 December 2020

Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure

1 reference

12 December 2020

Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum

1 reference

12 December 2020

Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis

1 reference

12 December 2020

The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection

1 reference

12 December 2020

Severe anaphylactic reaction to infliximab: report of a case

1 reference

12 December 2020

Anti?tumor necrosis factor therapy abrogates autoimmune demyelination

1 reference

12 December 2020

Prevention of chronic relapsing experimental autoimmune encephalomyelitis by soluble tumor necrosis factor receptor I

1 reference

12 December 2020

10.2165/00002018-200326010-00003

Identifiers

DOI

1 reference

Dimensions Publication ID

5 August 2017

1034818808

0 references

1 reference